At this time, the firm appears to be fairly valued. Bristol Myers Squibb shows a prevailing Real Value of $59.79 per share. The current price of the firm is $61.07. Our model approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as Current Valuation of 162.95 B, return on equity of -0.39, and Profit Margin of (0.19) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bristol Myers' valuation include:
Price Book
7.506
Enterprise Value
163 B
Enterprise Value Ebitda
51.4369
Price Sales
2.5658
Forward PE
8.9445
Fairly Valued
Today 61.07
Please note that Bristol Myers' price fluctuation is very steady at this time. Calculation of the real value of Bristol Myers Squibb is based on 3 months time horizon. Increasing Bristol Myers' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bristol Myers is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bristol Stock. However, Bristol Myers' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical
Market 61.07
Real 59.79
Target 61.01
Hype 61.07
Naive 58.0
The intrinsic value of Bristol Myers' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bristol Myers' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bristol Myers Squibb helps investors to forecast how Bristol stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bristol Myers more accurately as focusing exclusively on Bristol Myers' fundamentals will not take into account other important factors:
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bristol Myers' intrinsic value based on its ongoing forecasts of Bristol Myers' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bristol Myers' closest peers.
Bristol Myers Cash
10.86 Billion
Bristol Valuation Trend
Analysing the historical paterns of Bristol Myers' enterprise value and its market capitalization is a good way to estimate and gauge the value of Bristol Myers Squibb over time and is usually enough for investors to make rational market timing decisions.
Bristol Revenue by Product
Bristol Myers Total Value Analysis
Bristol Myers Squibb is currently expected to have company total value of 162.95 B with market capitalization of 123.93 B, debt of 51.2 B, and cash on hands of 9.12 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Bristol Myers fundamentals before making security assessment based on enterprise value of the company
About 81.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.38. Bristol Myers Squibb recorded a loss per share of 4.41. The entity last dividend was issued on the 4th of April 2025. The firm had 1000000:95 split on the 7th of August 2001. Based on the key indicators related to Bristol Myers' liquidity, profitability, solvency, and operating efficiency, Bristol Myers Squibb may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bristol Myers has an asset utilization ratio of 52.16 percent. This suggests that the Company is making $0.52 for each dollar of assets. An increasing asset utilization means that Bristol Myers Squibb is more efficient with each dollar of assets it utilizes for everyday operations.
Black Monday
Oil Shock
Dot-com Bubble
Housing Crash
Credit Downgrade
Yuan Drop
Covid
Bristol Myers Ownership Allocation
Bristol Myers holds a total of 2.03 Billion outstanding shares. The majority of Bristol Myers Squibb outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bristol Myers Squibb to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bristol Myers. Please pay attention to any change in the institutional holdings of Bristol Myers Squibb as this could imply that something significant has changed or is about to change at the company. Please note that on February 13, 2025, Representative Julie Johnson of US Congress acquired under $15k worth of Bristol Myers Squibb's common stock.
Bristol Myers Profitability Analysis
The company reported the last year's revenue of 48.3 B. Reported Net Loss for the year was (8.93 B) with profit before taxes, overhead, and interest of 36.35 B.
Our relative valuation model uses a comparative analysis of Bristol Myers. We calculate exposure to Bristol Myers's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bristol Myers's related companies.
Bristol Myers' stock price is the clearest measure of market expectations about its performance. Without stock valuation, investors cannot independently discern whether Bristol Myers' value is low or high relative to the company's performance and growth projections. Determining the market value of Bristol Myers can be done in different ways, such as multiplying its stock price by its outstanding shares.
A single share of Bristol Myers represents a small ownership stake in the entity. As a stockholder of Bristol, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
There are various types of dividends Bristol Myers can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Bristol shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Bristol Myers Squibb directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Bristol pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Bristol Myers by the value of the dividends paid out.
Bristol Myers Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding
2 B
Quarterly Earnings Growth Y O Y
-0.959
Forward Price Earnings
8.9445
Bristol Myers Current Valuation Indicators
Valuation refers to the process of determining the present value of Bristol Myers Squibb and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bristol we look at many different elements of the entity such as Bristol's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bristol Myers, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bristol Myers' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bristol Myers' worth.
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.